Pacira BioSciences, Inc.
NASDAQ:PCRXDrug Manufacturers - Specialty & Generic
-$0.18 today
- Market cap
- $1.46B
- Beta
- 0.29
- P/E (TTM)
- 176.9
- EPS (TTM)
- $0.13
Volume 1.81M
Average 0.57M
PCRX Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Pacira BioSciences, Inc.NASDAQ: PCRX
Total Assets · Q1 FY2026 · quarter ended Mar 2026
Total assets falls 23.8% from a year ago
Total assets stood at $1.21B at the end of Q1 FY2026, down 23.8% from a year earlier and down 4.5% from the prior quarter. Over 3 fiscal years it compounded at -9.0% a year.
Context
- Total assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -23.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 1.26B USD
- Year-over-year change
- -18.6%
- 4-year CAGR
- -11.6%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.26B | -18.6% |
| FY2024 | 2024-12-31 | 1.55B | -1.3% |
| FY2023 | 2023-12-31 | 1.57B | -6.4% |
| FY2022 | 2022-12-31 | 1.68B | -19.0% |
| FY2021 | 2021-12-31 | 2.08B | — |
Total Assets vs competitors
How PCRX compares with its peers on the latest reported figures
- PCRX's Mar 2026 total assets of $1.21B is the 3rd highest of the 4 companies compared; the peer median is $1.43B.
- Its year-over-year change of -23.8% is the lowest of 4, against a peer median of +3.3%.
- Over three fiscal years its annual growth of -9.0% compares with a peer median of +12.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
| Mar 2026 | $1.65B | +1.3% | +12.2% | |
| Jun 2026 | $1.43B | +3.3% | -5.2% | |
| Mar 2026 | $1.21B | -23.8% | -9.0% | |
| Mar 2026 | $293.64M | +271.8% | +61.6% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — |
| Peer median (excluding PCRX) | $1.43B | +3.3% | +12.2% | |
Competitors are the stored peer set for PCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 585.58M | 104.14M | 153.3M | 276.77M | 158.55M |
| Short-term Investments | 70.83M | 184.51M | 125.28M | 207.84M | 79.88M |
| Net Receivables | 96.32M | 98.4M | 105.56M | 113.3M | 124.07M |
| Inventory | 98.55M | 96.06M | 104.35M | 125.28M | 152.86M |
| Other Current Assets | 100K | 15.22M | 21.5M | 21.93M | 32.62M |
| Total Current Assets | 866.05M | 498.33M | 509.99M | 745.13M | 547.97M |
| Property, Plant & Equipment (Net) | 264.81M | 254.39M | 234.95M | 216.39M | 182.47M |
| Goodwill | 145.18M | 163.24M | 163.24M | 0 | 20.21M |
| Intangible Assets | 623.97M | 540.55M | 483.26M | 425.97M | 368.1M |
| Long-term Investments | 0 | 37.21M | 2.41M | 29.45M | 0 |
| Tax Assets | 153.36M | 160.31M | 144.49M | 130.38M | 123.85M |
| Other Non-current Assets | 21.99M | 27.17M | 36.05M | 6.2M | 22.31M |
| Total Non-current Assets | 1.21B | 1.18B | 1.06B | 808.39M | 716.94M |
| Total Assets | 2.08B | 1.68B | 1.57B | 1.55B | 1.26B |
| Account Payables | 10.54M | 15.22M | 15.7M | 19.13M | 15.15M |
| Short-term Debt | 374.7M | 33.65M | 8.64M | 201.78M | 9.84M |
| Tax Payables | 429K | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 45.49M | 26.2M | 42.56M | 28.81M | 95.6M |
| Total Current Liabilities | 521.12M | 147.77M | 97.38M | 309.92M | 120.59M |
| Long-term Debt | 674.53M | 655.82M | 513.8M | 383.55M | 408.37M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 4.21M |
| Deferred Revenue (Non-current) | 10.13M | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 67.45M | 37.79M | 38.27M | 37.06M | 2.46M |
| Total Non-current Liabilities | 823.83M | 758.42M | 606.87M | 465.25M | 451.22M |
| Total Liabilities | 1.34B | 906.19M | 704.26M | 775.17M | 571.81M |
| Common Stock | 45K | 46K | 46K | 47K | 48K |
| Retained Earnings | (211.9M) | (148.75M) | (106.8M) | (206.36M) | (199.32M) |
| Accumulated OCI | 167K | (380K) | 247K | 343K | 4.33M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 730.41M | 775.01M | 870.13M | 778.35M | 693.11M |
| Total Debt | 1.13B | 763.39M | 586.04M | 638.85M | 454.38M |
| Net Debt | 543.27M | 659.26M | 432.75M | 362.08M | 295.84M |
Pacira BioSciences, Inc.
NASDAQ:PCRX
Intrinsic Alpha fair value
Locked
Current Price
$36.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.